Breakdown | |||||
TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
431.86B | 435.08B | 426.68B | 335.14B | 297.18B | 333.37B | Gross Profit |
368.45B | 369.09B | 364.44B | 279.72B | 244.65B | 276.59B | EBIT |
153.96B | 171.46B | 149.00B | 110.31B | 117.44B | 130.63B | EBITDA |
191.79B | 217.81B | 176.41B | 143.42B | 158.67B | 174.47B | Net Income Common Stockholders |
168.61B | 162.03B | 184.97B | 114.19B | 111.86B | 122.19B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
305.58B | 358.09B | 563.36B | 465.18B | 418.32B | 380.02B | Total Assets |
1.52T | 1.42T | 1.31T | 1.15T | 998.99B | 871.53B | Total Debt |
23.06B | 11.62B | 9.41B | 6.67B | 7.99B | 8.15B | Net Debt |
-282.52B | -346.47B | -299.81B | -247.75B | -268.19B | -200.71B | Total Liabilities |
153.98B | 164.36B | 189.92B | 157.32B | 134.44B | 106.92B | Stockholders Equity |
1.35T | 1.24T | 1.10T | 975.66B | 846.11B | 764.56B |
Cash Flow | Free Cash Flow | ||||
189.90B | 126.02B | 140.68B | 70.50B | 76.09B | 120.17B | Operating Cash Flow |
206.82B | 154.28B | 177.87B | 102.07B | 109.04B | 131.94B | Investing Cash Flow |
-114.34B | 5.92B | -48.29B | -96.20B | -5.26B | -29.14B | Financing Cash Flow |
-79.37B | -126.85B | -84.12B | -36.62B | -43.89B | -88.17B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | ¥2.15T | 12.20 | 12.99% | 2.67% | 0.73% | 7.75% | |
71 Outperform | $1.13T | 24.43 | 5.34% | 4.20% | 6.42% | 11.00% | |
70 Outperform | $321.81B | 13.70 | 7.90% | 1.81% | 10.09% | 63.28% | |
69 Neutral | $255.38B | 7.81 | 11.16% | 3.01% | 20.05% | 94.28% | |
65 Neutral | ¥6.81T | 62.83 | 1.50% | 4.71% | 7.45% | -25.77% | |
57 Neutral | $324.59B | 13.52 | 13.50% | ― | 26.79% | ― | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% |
Shionogi & Co., Ltd. announced an amendment to its tender offer for shares of Torii Pharmaceutical Co., Ltd. due to a patent infringement lawsuit involving Torii’s oral antipruritus medication, REMITCH®. Despite the legal proceedings, Torii’s stance on the tender offer remains unchanged, as the financial implications of the lawsuit are still uncertain.
The most recent analyst rating on (JP:4507) stock is a Hold with a Yen2750.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
Shionogi & Co., Ltd. announced the acceptance of its New Drug Application for naldemedine, a treatment for opioid-induced constipation, in China. This approval is expected to enhance pain management options in China, where current treatments are limited, and improve the quality of life for patients. The drug, already available in several regions, demonstrated significant efficacy in a Phase III trial in China. Following approval, Shionogi China Co., Ltd. will handle sales through an exclusive agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd., potentially boosting Shionogi’s market presence and revenue in China.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen3100.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
Shionogi & Co., Ltd. has announced amendments to its tender offer for shares of Torii Pharmaceutical Co., Ltd., following a notice from the Japan Fair Trade Commission. These amendments, which do not alter the terms of purchase, are necessary to update the Tender Offer Statement and ensure compliance with regulatory requirements, reflecting the company’s commitment to adhere to legal standards in its acquisition efforts.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen3100.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
Shionogi & Co., Ltd. announced its decision to propose amendments to its Articles of Incorporation at the upcoming Annual General Meeting of Shareholders. The amendments aim to transition the company to a structure with an Audit and Supervisory Committee, enhancing corporate governance and facilitating strategic decision-making. This move is expected to strengthen oversight, promote globalization, and support business model transformation, potentially impacting the company’s operational efficiency and stakeholder engagement.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen3100.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
Shionogi & Co., Ltd. reported its consolidated financial results for the fiscal year 2024, showing a slight increase in revenue and operating profit compared to the previous year. The company conducted a 3-for-1 stock split effective October 2024, which impacted earnings per share calculations. Despite a decline in comprehensive income, the company forecasts significant growth in revenue and profit for the fiscal year ending March 2026, indicating a positive outlook for stakeholders.
Shionogi & Co., Ltd. has announced the commencement of a tender offer to acquire all shares of TORII PHARMACEUTICAL CO., LTD., aiming to make it a wholly-owned subsidiary. This strategic move is part of a broader transaction involving stock consolidation and capital restructuring, which is expected to enhance Shionogi’s market position and operational capabilities by integrating TORII’s resources and expertise.
Shionogi & Co., Ltd. announced a strategic move to acquire the pharmaceutical business of Japan Tobacco Inc. and make Akros Pharma Inc. a sub-subsidiary, enhancing its capabilities in small molecule drug discovery. This transaction aligns with Shionogi’s vision of creating a new healthcare platform and aims to accelerate the development of innovative drugs, strengthen its global market position, and contribute to global health by delivering advanced pharmaceuticals.
Shionogi & Co. announced an increase in its dividend forecasts for the fiscal year ending March 31, 2025, reflecting its commitment to shareholder returns and corporate value growth. The company has achieved revenue stability in its domestic market through its respiratory infection treatments and is expanding its global presence with Cefiderocol. Additionally, Shionogi is advancing its COVID-19 treatment, Ensitrelvir, through clinical trials and regulatory discussions, while benefiting from increased royalties from its HIV franchise. The dividend increase is part of Shionogi’s strategy to enhance shareholder value, supported by its strong financial performance and strategic investments.
Shionogi & Co., Ltd. has initiated a rolling submission of a new drug application with the U.S. FDA for its oral antiviral ensitrelvir, intended for post-exposure prophylaxis of COVID-19. This submission follows positive results from the SCORPIO-PEP Phase 3 study, which demonstrated the drug’s efficacy in preventing symptomatic COVID-19. If approved, ensitrelvir would be the first orally-administered option for post-exposure prophylaxis of COVID-19, potentially enhancing Shionogi’s market position and offering a new preventive measure amid decreasing vaccination rates and emerging variants.
Shionogi & Co., Ltd. has submitted a supplemental New Drug Application in Japan for its oral antiviral drug, ensitrelvir, intended for post-exposure prophylaxis of COVID-19. If approved, it will be the first oral option for this purpose, enhancing Shionogi’s position in the antiviral market. The application is supported by positive results from a Phase 3 study, which demonstrated the drug’s efficacy in preventing COVID-19 in exposed individuals. This development could significantly impact COVID-19 management, offering a new preventive measure amid challenges with vaccination rates and emerging variants.
Shionogi & Co., Ltd. announced its decision to transition to a Company with an Audit and Supervisory Committee, aiming to enhance oversight and streamline decision-making processes. This transition, pending shareholder approval, is expected to strengthen the company’s governance structure and support its strategic goals, including globalization and business model transformation, while maintaining a diverse and skilled Board of Directors.
Shionogi & Co., Ltd. announced promising results from its Phase 3 trial of ensitrelvir, an oral antiviral drug, which showed a significant reduction in the risk of developing COVID-19 when used as post-exposure prophylaxis. This development positions ensitrelvir as a potential breakthrough in preventing COVID-19, especially for high-risk individuals, and highlights Shionogi’s commitment to addressing unmet medical needs in infectious disease prevention.